JP2006525318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006525318A5 JP2006525318A5 JP2006507687A JP2006507687A JP2006525318A5 JP 2006525318 A5 JP2006525318 A5 JP 2006525318A5 JP 2006507687 A JP2006507687 A JP 2006507687A JP 2006507687 A JP2006507687 A JP 2006507687A JP 2006525318 A5 JP2006525318 A5 JP 2006525318A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- hydroxy
- amino
- methylethyl
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 25
- -1 C 1 -C 3 alkyl group compound Chemical class 0.000 claims description 23
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 12
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 12
- 208000020629 overactive bladder Diseases 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000027939 micturition Effects 0.000 description 24
- 241000700159 Rattus Species 0.000 description 20
- 210000003932 urinary bladder Anatomy 0.000 description 16
- 230000008602 contraction Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 208000013403 hyperactivity Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000036977 tonic contraction Effects 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- VMMYRRFPMAGXNP-BTYIYWSLSA-N 2-[4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC(C)=C(OCC(O)=O)C=C1C VMMYRRFPMAGXNP-BTYIYWSLSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 230000008925 spontaneous activity Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 3
- 229960004045 tolterodine Drugs 0.000 description 3
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100033902 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 208000020339 Spinal injury Diseases 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 201000002327 urinary tract obstruction Diseases 0.000 description 2
- XRLNLENEMPYBGI-NVJCMEIXSA-N 2-[4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid;hydrochloride Chemical compound Cl.N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC(C)=C(OCC(O)=O)C=C1C XRLNLENEMPYBGI-NVJCMEIXSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- PYGMUIGIQUMVGV-ZOEDVAEJSA-N C(C)(=O)O.O[C@@H]([C@H](C)NCCC1=CC(=C(OCCCl)C=C1C)C)C1=CC=C(C=C1)O Chemical compound C(C)(=O)O.O[C@@H]([C@H](C)NCCC1=CC(=C(OCCCl)C=C1C)C)C1=CC=C(C=C1)O PYGMUIGIQUMVGV-ZOEDVAEJSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000036724 intravesical pressure Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003510 propiverine Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10320084A DE10320084A1 (de) | 2003-05-05 | 2003-05-05 | Verwendung von Phenoxyessigsäurederivaten zur Behandlung der hyperaktiven Blase |
| DE2003123837 DE10323837A1 (de) | 2003-05-23 | 2003-05-23 | Verwendung von Phenoxyessigsäurederivaten zur Behandlung der hyperaktiven Blase |
| PCT/JP2004/004048 WO2004098586A1 (en) | 2003-05-05 | 2004-03-24 | Use of phenoxyacetic acid derivatives for treating hyperactive bladder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006525318A JP2006525318A (ja) | 2006-11-09 |
| JP2006525318A5 true JP2006525318A5 (https=) | 2009-05-14 |
| JP4602969B2 JP4602969B2 (ja) | 2010-12-22 |
Family
ID=33420009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507687A Expired - Fee Related JP4602969B2 (ja) | 2003-05-05 | 2004-03-24 | 過活動膀胱を治療するためのフェノキシ酢酸誘導体の使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040229947A1 (https=) |
| EP (1) | EP1620085B1 (https=) |
| JP (1) | JP4602969B2 (https=) |
| KR (1) | KR101052804B1 (https=) |
| AR (1) | AR044169A1 (https=) |
| AT (1) | ATE401878T1 (https=) |
| AU (1) | AU2004236596B2 (https=) |
| BR (1) | BRPI0409980A (https=) |
| CA (1) | CA2524023C (https=) |
| CL (1) | CL2004000952A1 (https=) |
| CY (1) | CY1108425T1 (https=) |
| DE (1) | DE602004015272D1 (https=) |
| DK (1) | DK1620085T3 (https=) |
| ES (1) | ES2309513T3 (https=) |
| IL (1) | IL171713A (https=) |
| MX (1) | MXPA05011862A (https=) |
| MY (1) | MY141756A (https=) |
| NZ (1) | NZ543347A (https=) |
| PE (1) | PE20050524A1 (https=) |
| PL (1) | PL1620085T3 (https=) |
| PT (1) | PT1620085E (https=) |
| RU (1) | RU2342133C2 (https=) |
| SI (1) | SI1620085T1 (https=) |
| TW (1) | TWI351279B (https=) |
| UY (1) | UY28306A1 (https=) |
| WO (1) | WO2004098586A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI356699B (en) | 2004-11-10 | 2012-01-21 | Kissei Pharmaceutical | Agent for treating interstitial cystitis and agent |
| CA2605298A1 (en) * | 2005-04-26 | 2006-11-09 | Kissei Pharmaceutical Co., Ltd. | Crystal of hydroxynorephedrin derivative hydrochloride 1/4 hydrate |
| US7763654B2 (en) * | 2005-04-26 | 2010-07-27 | Kissei Pharmaceutical Co., Ltd. | Crystal polymorph of hydroxynorephedrin derivative hydrochloride |
| EP1769792A1 (de) * | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
| EP4410295A3 (en) | 2017-06-06 | 2024-10-16 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254469B (it) * | 1992-02-25 | 1995-09-25 | Recordati Chem Pharm | Derivati benzopiranici e benzotiopiranici |
| US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
| US6720014B1 (en) * | 1997-08-13 | 2004-04-13 | Diversa Corporation | Phytase-containing foodstuffs and methods of making and using them |
| MY126489A (en) * | 1998-07-08 | 2006-10-31 | Kissei Pharmaceutical | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
| US6410484B1 (en) * | 1999-11-01 | 2002-06-25 | Sumitomo Chemical Company, Limited | 6-Hydroxy-5,6-dihydrouracil compound and herbicidal composition containing thereof |
| MXPA04002449A (es) * | 2001-09-13 | 2004-07-23 | Kissei Pharmaceutical | Cristales de derivado de hidroxinorefedrina. |
-
2004
- 2004-03-24 DE DE602004015272T patent/DE602004015272D1/de not_active Expired - Lifetime
- 2004-03-24 WO PCT/JP2004/004048 patent/WO2004098586A1/en not_active Ceased
- 2004-03-24 JP JP2006507687A patent/JP4602969B2/ja not_active Expired - Fee Related
- 2004-03-24 AT AT04722967T patent/ATE401878T1/de active
- 2004-03-24 EP EP04722967A patent/EP1620085B1/en not_active Expired - Lifetime
- 2004-03-24 MX MXPA05011862A patent/MXPA05011862A/es active IP Right Grant
- 2004-03-24 KR KR1020057020792A patent/KR101052804B1/ko not_active Expired - Fee Related
- 2004-03-24 CA CA2524023A patent/CA2524023C/en not_active Expired - Fee Related
- 2004-03-24 BR BRPI0409980-0A patent/BRPI0409980A/pt not_active IP Right Cessation
- 2004-03-24 NZ NZ543347A patent/NZ543347A/en not_active IP Right Cessation
- 2004-03-24 RU RU2005137701/15A patent/RU2342133C2/ru not_active IP Right Cessation
- 2004-03-24 AU AU2004236596A patent/AU2004236596B2/en not_active Ceased
- 2004-03-24 ES ES04722967T patent/ES2309513T3/es not_active Expired - Lifetime
- 2004-03-24 PL PL04722967T patent/PL1620085T3/pl unknown
- 2004-03-24 PT PT04722967T patent/PT1620085E/pt unknown
- 2004-03-24 SI SI200430884T patent/SI1620085T1/sl unknown
- 2004-03-24 DK DK04722967T patent/DK1620085T3/da active
- 2004-03-26 US US10/809,346 patent/US20040229947A1/en not_active Abandoned
- 2004-04-21 TW TW093111093A patent/TWI351279B/zh not_active IP Right Cessation
- 2004-04-30 MY MYPI20041651A patent/MY141756A/en unknown
- 2004-05-04 CL CL200400952A patent/CL2004000952A1/es unknown
- 2004-05-05 PE PE2004000459A patent/PE20050524A1/es not_active Application Discontinuation
- 2004-05-05 AR ARP040101519A patent/AR044169A1/es not_active Application Discontinuation
- 2004-05-05 UY UY28306A patent/UY28306A1/es unknown
-
2005
- 2005-11-01 IL IL171713A patent/IL171713A/en not_active IP Right Cessation
-
2008
- 2008-10-16 CY CY20081101158T patent/CY1108425T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009151695A4 (en) | Compounds and method for reducing uric acid | |
| JP5477881B2 (ja) | （＋）−トラマドール、ｏ−デメチルトラマドール又は（＋）−ｏ−デメチルトラマドール、ｏ−デスメチル−ｎ−モノ−デスメチル−トラマドール又は（＋）−ｏ−デスメチル−ｎ−モノ−デスメチル−トラマドールを尿失禁の治療に使用する方法 | |
| JP2005507387A5 (https=) | ||
| US6841575B2 (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for treatment of urinary incontinence | |
| JP2006525318A5 (https=) | ||
| JP4602969B2 (ja) | 過活動膀胱を治療するためのフェノキシ酢酸誘導体の使用 | |
| US7361690B2 (en) | Compositions and methods for the treatment of urinary incontinence | |
| CN1321634C (zh) | 6－二甲基氨基甲基－1－苯基－环己烷化合物治疗尿失禁的用途 | |
| JP2004524280A5 (https=) | ||
| JP7113434B2 (ja) | 過活動膀胱の予防剤または治療剤 | |
| CN100518731C (zh) | 苯氧基乙酸衍生物用于制备治疗机能亢进性膀胱的药物 | |
| US20040068006A1 (en) | Method for preventing acute renal failure | |
| HK1061355B (en) | Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence |